Xanthopsia from Jaundice

What is Xanthopsia from jaundice?

Xanthopsia (from the Greek xanthos meaning “yellow” and opsis meaning “vision”) is a visual disturbance in which objects appear yellow‑tinted. When it occurs in the setting of jaundice, the yellow hue is not a trick of the mind alone – it reflects the accumulation of bilirubin (a yellow pigment) in the bloodstream and, in severe cases, the central nervous system.

Jaundice itself is a clinical sign of hyperbilirubinemia, most often manifesting as yellowing of the skin and sclerae. In a subset of patients with markedly elevated bilirubin levels, especially when the blood‑brain barrier is compromised, bilirubin can affect retinal photoreceptors and cortical processing, leading to xanthopsia. The phenomenon is rare but clinically important because its presence signals that bilirubin concentrations may be reaching neurotoxic levels.

Understanding xanthopsia in the context of jaundice helps clinicians gauge the urgency of treatment and alerts patients to seek prompt medical care.

Common Causes

While any condition that raises serum bilirubin can theoretically cause xanthopsia, the following 9 disorders are most frequently associated:

• Hemolytic anemia – rapid destruction of red blood cells releases large amounts of unconjugated bilirubin.
• Acute viral hepatitis (A, B, C, D, E) – hepatocellular injury impairs bilirubin conjugation.
• Drug‑induced liver injury – acetaminophen overdose, isoniazid, certain antibiotics, and antiretrovirals.
• Gallstone obstruction (choledocholithiasis) – blocks bile flow, causing conjugated hyperbilirubinemia.
• Primary biliary cholangitis & primary sclerosing cholangitis – chronic cholestatic diseases.
• Neonatal physiologic jaundice – immature liver enzyme systems; severe cases can lead to kernicterus with visual disturbances.
• Genetic disorders – Crigler‑Najjar syndrome type I/II, Gilbert syndrome (usually mild, but can exacerbate other causes).
• Sepsis or severe inflammatory states – cytokine‑mediated hepatocellular dysfunction.
• Pancreatic or peri‑ampullary tumors – compress the distal bile duct, leading to obstructive jaundice.

Associated Symptoms

Patients with xanthopsia rarely experience the visual change in isolation. Typical accompanying features include:

• Classic jaundice signs – yellowing of the sclerae, skin, and mucous membranes.
• Dark urine and pale stools (indicative of conjugated bilirubin excretion problems).
• Pruritus (itching) caused by bile salts depositing in the skin.
• Fatigue, malaise, and anorexia – common to most hepatic illnesses.
• Abdominal discomfort or right‑upper‑quadrant pain (gallbladder, liver capsule distension).
• Fever or chills if an infectious etiology (e.g., cholangitis) is present.
• Neurological changes in severe hyperbilirubinemia: lethargy, confusion, asterixis, or even seizures.
• In neonates – poor feeding, high‑pitch cry, and hypotonia (early signs of bilirubin encephalopathy).

When to See a Doctor

Because xanthopsia may signal dangerously high bilirubin, patients should seek medical attention promptly if they notice any of the following:

• Yellow‑tinged vision that does not resolve within a few hours.
• Visible jaundice of the eyes or skin, especially if it spreads rapidly.
• Dark urine, pale stools, or severe itching.
• Abdominal pain that is persistent, worsening, or accompanied by fever.
• New confusion, difficulty concentrating, slurred speech, or abnormal movements.
• In infants, any yellow discoloration of the skin or eyes plus poor feeding or lethargy.

Early evaluation can prevent progression to bilirubin‑induced neurologic injury, which may become irreversible.

Diagnosis

Evaluation follows a stepwise approach that combines visual symptom assessment, laboratory testing, and imaging.

1. Clinical History & Physical Examination

• Ask about the onset, duration, and progression of visual changes.
• Identify risk factors: recent infections, medication use, alcohol intake, family history of liver disease, or hemolytic disorders.
• Perform a thorough exam focusing on scleral icterus, skin coloration, abdominal tenderness, and neurologic status.

2. Laboratory Tests

• Serum bilirubin – total, direct (conjugated), and indirect (unconjugated). Levels >20 mg/dL (≈340 µmol/L) markedly increase the risk of neurotoxicity.
• Liver enzymes – ALT, AST, ALP, GGT to distinguish hepatocellular vs. cholestatic patterns.
• Complete blood count – looks for hemolysis (low Hb, elevated reticulocyte count) or infection.
• Coagulation profile – PT/INR; severe liver dysfunction often prolongs clotting times.
• Additional tests as indicated: viral hepatitis serologies, auto‑immune panels, ferritin, ceruloplasmin.

3. Imaging Studies

• Abdominal ultrasound – first‑line to detect gallstones, biliary dilation, or liver parenchymal disease.
• Magnetic resonance cholangiopancreatography (MRCP) – non‑invasive delineation of the bile ducts.
• CT scan – useful when a tumor or pancreatic pathology is suspected.

4. Specialized Ophthalmic Evaluation

While not always required, an eye specialist may perform:

• Color vision testing (e.g., Farnsworth‑Munsell 100‑Hue test) to objectively document yellow hue perception.
• Fundoscopic exam – rare bilirubin deposits in the retina may be seen in severe cases.

5. Neuro‑imaging (Rare)

If neurological deterioration occurs, MRI of the brain can reveal bilirubin deposition in the basal ganglia (kernicterus) – a medical emergency.

Treatment Options

Therapy focuses on lowering serum bilirubin, treating the underlying cause, and protecting the nervous system.

1. Address the Underlying Etiology

• Hemolysis – stop offending drugs, treat underlying immune hemolytic anemia with steroids or immunoglobulin, transfuse packed red cells if needed.
• Viral hepatitis – antiviral agents (e.g., sofosbuvir/velpatasvir for HCV), supportive care, and avoidance of hepatotoxic substances.
• Obstructive jaundice – Endoscopic retrograde cholangiopancreatography (ERCP) with stone extraction or stent placement; surgical biliary bypass in select cases.
• Drug‑induced injury – Immediate discontinuation of the culprit medication; N‑acetylcysteine for acetaminophen toxicity.

2. Lower Bilirubin Levels Directly

• Phototherapy – Uses blue‑green light to convert bilirubin into water‑soluble isomers that can be excreted without conjugation. First‑line for neonates; occasionally employed in adults with extreme hyperbilirubinemia.
• Exchange transfusion – Rapid removal of bilirubin‑rich plasma; indicated when bilirubin >30 mg/dL or if neurologic signs appear.
• Intravenous immunoglobulin (IVIG) – Helpful in immune‑mediated hemolysis to reduce bilirubin production.
• Bile acid sequestrants (e.g., cholestyramine) – May aid in removal of conjugated bilirubin in cholestatic disease.

3. Supportive & Home Measures

• Maintain adequate hydration to promote renal clearance of bilirubin.
• Consume a balanced diet rich in protein and moderate in healthy fats; avoid excessive alcohol.
• Apply soothing lotions or antihistamine creams for pruritus.
• Monitor visual changes; keep a symptom diary to share with your clinician.

4. Follow‑up Care

Patients should have repeat bilirubin measurements 12–24 hours after initiating therapy, with more frequent checks if levels are >20 mg/dL. Long‑term surveillance may include liver function monitoring and imaging to detect chronic complications.

Prevention Tips

While not all causes of jaundice are preventable, many strategies reduce the risk of severe hyperbilirubinemia and thus xanthopsia:

• Vaccination against hepatitis A and B.
• Practice safe sex and avoid sharing needles to reduce hepatitis C transmission.
• Limit alcohol intake; follow guidelines—no more than 2 drinks per day for men, 1 for women.
• Use medications as prescribed; avoid over‑the‑counter acetaminophen >4 g/day.
• Promptly treat infections, especially in patients with known liver disease.
• For newborns, ensure early feeding and follow pediatric bilirubin screening protocols (e.g., transcutaneous bilirubinometry).
• Maintain a healthy weight and manage diabetes, which can predispose to fatty liver disease and cholestasis.
• Regular medical check‑ups for those with chronic liver conditions (e.g., primary biliary cholangitis) to adjust therapy before bilirubin spikes.

Emergency Warning Signs

---

**References**

• Mayo Clinic. “Jaundice.” Accessed May 2024. https://www.mayoclinic.org/diseases-conditions/jaundice
• National Institutes of Health (NIH). “Hyperbilirubinemia in adults.” UpToDate, 2023.
• World Health Organization. “Viral Hepatitis Fact Sheet.” Updated 2022.
• Cleveland Clinic. “Phototherapy for Hyperbilirubinemia.” 2023.
• American Academy of Pediatrics. “Management of Hyperbilirubinemia in the Newborn.” 2022.
• Harvard Health Publishing. “When Jaundice Means Trouble.” 2023.